Pfizer Inc. v. Government of India

1978-02-27

Headline: Antitrust ruling allows foreign governments to sue U.S. companies for triple damages, making it easier for countries that bought antibiotics to recover money and increasing liability for American suppliers.

Holding: The Court held that a foreign nation injured in its business or property may sue in U.S. courts for treble damages under the antitrust laws because a foreign sovereign can be a "person" entitled to that remedy.

Real World Impact:

Lets foreign governments seek triple money awards against U.S. companies for antitrust harm.
Increases potential liability and deterrence for companies doing business abroad.
Raises foreign‑policy and litigation concerns noted by dissenters.

Topics: antitrust lawsuits, foreign governments suing, triple damages, pharmaceutical price fixing

Summary

Background

The Governments of India, Iran, and the Philippines sued six U.S. pharmaceutical manufacturers, alleging price fixing, market division, and fraud over broad‑spectrum antibiotics. The countries said they were damaged as purchasers and sought treble damages (triple the money award) under the Clayton Act. Lower courts refused to dismiss the suits and the issue reached this Court: whether a foreign nation counts as a "person" who may recover treble damages.

Reasoning

The Court focused on the meaning of the word "person" in the statute and the statutes' purposes. It noted that the antitrust laws reach foreign commerce and that Congress explicitly treated foreign corporations as within the statute. Relying on prior decisions and the remedial goals of deterring illegal conduct and compensating victims, the Court concluded that foreign sovereigns may be "persons" able to sue for treble damages when injured in their business or property. The decision also stressed existing rules of comity and that the Executive still controls recognition of foreign governments for access to U.S. courts.

Real world impact

The ruling permits foreign governments that buy goods to bring treble‑damages suits in U.S. courts, potentially increasing exposure for U.S. companies accused of anticompetitive conduct abroad. The opinion resolved a procedural threshold: it allows these suits to proceed but does not decide whether the companies actually committed antitrust violations.

Dissents or concurrances

A dissent argued this policy change should be left to Congress and warned of broad foreign‑policy and practical consequences, noting legislative history and sovereign‑immunity considerations.